Question · asked by 1 review
Superoxide dismutase (SOD) vs placebo: Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs)
- Population
- preterm infants at risk for bronchopulmonary dysplasia
- Intervention
- Superoxide dismutase (SOD)
- Comparison
- placebo
- Outcome
- Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs)
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Superoxide dismutase (SOD) vs placebo Moderate to severe neurodevelopmental outcome at 18 to 24 months№ of participants: 0 (0 RCTs) · preterm infants at risk of developing BPD The review found no eligible studies for this question. Superoxide dismutase for bronchopulmonary dysplasia in preterm infants (2023) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Superoxide dismutase for bronchopulmonary dysplasia in preterm infants 2023 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.